Prelude Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies targeting cancer. Its primary function is to advance the understanding of molecular diseases and design precision therapies aimed at challenging hematologic malignancies and solid tumors. The company's research is deeply rooted in understanding the intricate biological pathways driving cancer, which allows them to identify novel targets for drug development. Prelude's pipeline consists of a range of compounds in various phases of development, each tailored to inhibit specific cancer-causing proteins and pathways. Operating predominantly in the biopharmaceutical and healthcare sectors, Prelude Therapeutics impacts both the scientific community and the pharmaceutical industry by contributing to the advancement of targeted cancer therapies. The company plays a significant role in the ongoing evolution of precision medicine, striving to offer more personalized and effective treatment options that can potentially improve outcomes and quality of life for patients battling cancer.